Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Shanehbandi, Dariush  [Clear All Filters]
2023
Sayadmanesh A, Azadbakht M, Yari K, Abedelahi A, Shafaei H, Shanehbandi D, Baradaran B, Basiri M. Characterization of CAR T Cells Manufactured Using Genetically Engineered Artificial Antigen Presenting Cells. Cell J. 2023;25(10):674-687.
Danaiyan S, Abbasi MMesgari, Raeisi S, Argani H, Ghorbanihaghjo A, Shanehbandi D, Roshangar L, Poursistany H, Abedi S, Mohammadian J, et al. The Effects of Remdesivir and Dexamethasone on Renal Sirtuin-1 Expression and Renal Function in Male Rats. Appl Biochem Biotechnol. 2023.
Sayadmanesh A, Yekehfallah V, Valizadeh A, Abedelahi A, Shafaei H, Shanehbandi D, Basiri M, Baradaran B. Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer. Int Immunopharmacol. 2023;125(Pt A):111093.
2022
Pourradi NMohammad A, Babaei H, Hamishehkar H, Baradaran B, Shokouhi-Gogani B, Shanehbandi D, Ghorbani M, Azarmi Y. Targeted delivery of doxorubicin by Thermo/pH-responsive magnetic nanoparticles in a rat model of breast cancer. Toxicol Appl Pharmacol. 2022:116036.
2021
Asadzadeh Z, Mansoori B, Mohammadi A, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Hemmat N, Derakhshani A, Brunetti O, Safaei S, et al. The combination effect of Prominin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. Biomed Pharmacother. 2021;137:111364.
2019
Akbari M, Shanehbandi D, Asadi M, Shomali N, Faraji A, Khaze V, Pakdel A, Mokhtarzadeh A, Ebrahimi AAsghar, Shabani A, et al. Effects of CD133 Silencing on Survival and Migration of HT-29 Colorectal Cancer Cells. Iran J Immunol. 2019;16(3):246-257.